Leerink Partnrs dropped their FY2024 earnings per share estimates for shares of United Therapeutics in a research report ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

United Therapeutics (UTHR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more ...

Stock analysts at Leerink Partnrs reduced their FY2024 EPS estimates for shares of United Therapeutics in a research note issued on Tuesday, February 11th. Leerink Partnrs analyst R. Ruiz now expects ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., January 21, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five posters across its ...

The U.S. Food and Drug Administration has cleared United Therapeutics (Nasdaq: UTHR) to begin a clinical trial that involves transplanting kidneys of gene-edited pigs into people with kidney failure.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BTIG analyst Julian Harrison maintained a Hold rating on United Therapeutics (UTHR – Research Report) on January 21. The company’s shares ...

UTHR boasts an average earnings surprise of 4.2%. On a historic basis, United Therapeutics has generated cash flow growth of 10.7%, and is expected to report cash flow expansion of 33.3% this year.